Browse the latest forensic toxicology articles or search the collection.
-
High Adherence, No Clear Benefit: Naltrexone Alone in a Methamphetamine Trial
A 100-person placebo-controlled trial separates successful delivery of monthly naltrexone injections from evidence that the medication reduced methamphetamine use.
-
What Does a 13.6% Response Mean in the Methamphetamine Naltrexone–Bupropion Trial?
The ADAPT-2 result was a weighted response under a specific urine-testing rule, not a 13.6% cure rate or continuous-abstinence estimate.
-
Does an Ethanol Assay’s Measurement Uncertainty Cover Postmortem Formation?
A validated GC–FID method quantified analytical uncertainty in road-traffic blood testing. That uncertainty does not measure microbial formation or reconstruct ethanol concentration before death.
-
Glucose, pH and Candida: Why Postmortem Ethanol Yield Depends on the Specimen
A controlled blood-surrogate experiment found much more fungal ethanol after glucose addition. The results describe manipulated culture conditions, not a correction based on a diabetes diagnosis.
-
What 4°C Candida Controls Can Show About Postmortem Ethanol Preservation
A fungal experiment found no alcohol production in refrigerated broth controls. That finding supports a defined temperature effect, not retrospective proof of an autopsy specimen’s origin.
-
What Does 62% Model Agreement Mean in Postmortem Ethanol Research?
A 122-case study counted predictions within ±40% of measured ethanol as successful. That endpoint is not diagnostic accuracy for identifying how much ethanol formed after death.
-
Does Absent 1-Propanol Exclude Microbial Ethanol Formation?
Controlled cultures produced ethanol without measurable 1-propanol under some conditions. A negative single-congener result cannot function as a universal exclusion test.
-
What Does Reduced Long-Term Potentiation Mean in Methamphetamine Research?
A 2026 narrative review links methamphetamine exposure with synaptic-plasticity mechanisms. Laboratory LTP, memory performance and individual impairment remain different endpoints.
-
Can a Mixed-Stimulant Survey Establish Methamphetamine-Specific Overdose Rates?
A New England survey included methamphetamine, cocaine and other stimulant histories. Its self-reported overdose and emergency-call figures cannot be assigned to methamphetamine alone.
-
Can a Sweat Assay’s Lower Number Prove Greater Amphetamine Sensitivity Than a Blood Assay?
A 2024 sweat-method paper illustrates why ng/patch and ng/mL cannot be ranked by numerical size. Validation limits and authentic-sample findings must also stay separate.
-
Can an Amphetamine-Class Sweat Screen Identify Methamphetamine? A 66-Driver Study
A roadside sweat study validated amphetamine and methamphetamine measurement but confirmed neither in its driver samples. A class screen and an identified analyte answer different questions.
-
Were Methamphetamine-Related Social-Cognition Differences the Largest—or Just the Least Studied?
A 44-study meta-analysis found a large social-cognition difference based on only three studies. Effect magnitude, evidence volume and individual prediction are separate issues.
-
Is Amphetamine Simply a Dopamine Reuptake Blocker? What Transporter Pharmacology Adds
Amphetamine can act as a transporter substrate and promote monoamine release. A historical pharmacology review explains why that differs from simply blocking reuptake.
-
What Evidence Would Show That Methamphetamine Caused Cognitive Decline? A Six-Part Review
A historical review examined six lines of causal evidence. Animal experiments, twin comparisons and abstinence studies each answer part of the question and retain important limits.
-
Should Methamphetamine Treatment Research Measure Recovery Beyond Days of Use?
A 2025 scientific opinion argues for studying withdrawal, cognition and functioning alongside methamphetamine use. Its proposed research agenda is not proof that candidate treatments work.
-
Does an Amphetamine Patch NNT of Three Predict Benefit for Every New Patient?
A patch trial’s number needed to treat depended on the endpoint and on prior open-label dose optimization. It is not a universal probability of benefit when starting treatment.
-
What Does an Executive-Function “Responder” Mean in Mixed Amphetamine Salts Research?
Two post hoc analyses used a 40-item self-report scale to define executive-function response. Their thresholds, available denominators and relation to actual performance matter.
-
Can a Small Attention Pilot Establish That Lisdexamfetamine Outlasts Immediate-Release Amphetamine?
An 18-adult crossover pilot produced descriptive attention estimates through 16 hours. It did not conduct inferential comparisons establishing one active drug’s superiority.
-
Do More Dextroamphetamine Adverse-Event Reports Mean Greater Risk? The Missing Denominator
A 2025 pharmacovigilance comparison counted reports, reactions and reporting signals. None supplies the number of exposed patients needed to estimate incidence.
-
Lisdexamfetamine and Childhood Growth: What a Historical Norm Comparison Can Show
A historical analysis compared growth in 281 treated children with population norms. Reduced expected gains and measured weight loss require different descriptions.